GKOS - Wutah dodolan YoY (TTM) glaukos.com

Logo grafis Glaukos Corporation (GKOS)

Glaukos Corporation (GKOS) is implementing microtechnologies and automation to control drug dosing for glaucoma. This chart on GURU.Markets shows that the trailing twelve months (TTM) annual growth in operating sales revenue stands at 46.30. This trend captures a backdrop of geopolitical risks disrupting implant logistics, coupled with an R&D breakthrough via the commercial launch of the innovative iDose TR microimplant.

GKOS Glaukos: Wutah dodolan YoY sajrone rolas wulan kepungkur ing interval 11.02.2024 - 18.11.2026

Ringkesan rincian data analitis Glaukos Corp (GKOS)

- rega saham lan target rega konsensus:
Pambiji fundamental perusahaan:Glaukos Corp.
Produk asil prodhuksi Glaukos

Glaukos Corporation maintains sustainable market demand driven by its pioneer status in microinvasive glaucoma surgery and its iStent implant patents. This competitive advantage is reflected in the monetary value of the rolling twelve-month annual revenue growth. This metric measures the actual volume of incremental inflows, filtering out short-term volatility and noise. Analyzing the relative sales growth over a 12-month period compared to the previous year provides an objective assessment of the business's fundamental expansion.